Legato Capital Management LLC Has $2.45 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Legato Capital Management LLC grew its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 48.1% in the 4th quarter, Holdings Channel reports. The fund owned 29,364 shares of the biopharmaceutical company’s stock after buying an additional 9,541 shares during the period. Legato Capital Management LLC’s holdings in Intra-Cellular Therapies were worth $2,452,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ITCI. China Universal Asset Management Co. Ltd. grew its holdings in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after purchasing an additional 2,157 shares during the last quarter. Barclays PLC boosted its position in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after buying an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC boosted its position in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after buying an additional 8,440 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Intra-Cellular Therapies by 31.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after buying an additional 109,892 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of Intra-Cellular Therapies by 3.3% in the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after acquiring an additional 18,865 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Price Performance

ITCI stock opened at $127.56 on Wednesday. The stock has a 50-day moving average price of $102.37 and a 200-day moving average price of $86.66. Intra-Cellular Therapies, Inc. has a 1-year low of $62.78 and a 1-year high of $128.00.

Analysts Set New Price Targets

ITCI has been the topic of a number of research reports. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. StockNews.com began coverage on Intra-Cellular Therapies in a report on Saturday. They set a “hold” rating on the stock. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Piper Sandler reissued a “neutral” rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. upped their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.